Literature DB >> 16424217

Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma.

Amr El-Shazly1, Patrick Berger, Pierre-Olivier Girodet, Olga Ousova, Michael Fayon, Jean-Marc Vernejoux, Roger Marthan, J Manuel Tunon-de-Lara.   

Abstract

Human airway smooth muscle cells (HASMC) secrete fractalkine (FKN), a chemokine the concentration of which is increased in asthmatic patients. HASMC also induce mast cell chemotaxis, as a component of asthma inflammation. We therefore evaluated the role of smooth muscle-derived FKN in mast cell migration. We assessed the capacity of recombinant FKN to induce human mast cell chemotaxis. This effect implicates a calcium-independent pathway involving actin reorganization and protein kinase C-delta. We found that HASMC constitutively produce FKN, the synthesis of which is reinforced upon proinflammatory stimulation. Under basal experimental conditions, FKN production by HASMC is not sufficient to induce mast cell chemotaxis. However, pretreatment of mast cells with the neuropeptide vasoactive intestinal peptide (VIP) increases FKN potency to attract mast cells. Since we observed, in asthmatic patients, an increase in both FKN and VIP expression by airway smooth muscle and a positive correlation between VIP staining and mast cell infiltration of the smooth muscle layer, we conclude that HASMC-derived FKN may contribute to mast cell recruitment in asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424217     DOI: 10.4049/jimmunol.176.3.1860

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung.

Authors:  Cyrille Mionnet; Vanessa Buatois; Akira Kanda; Valerie Milcent; Sebastien Fleury; David Lair; Marie Langelot; Yannick Lacoeuille; Edith Hessel; Robert Coffman; Antoine Magnan; David Dombrowicz; Nicolas Glaichenhaus; Valerie Julia
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

2.  Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages.

Authors:  Michael Miksa; Dhruv Amin; Rongqian Wu; Thanjavur S Ravikumar; Ping Wang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

3.  Inflammation of bronchial smooth muscle in allergic asthma.

Authors:  H Begueret; P Berger; J M Vernejoux; L Dubuisson; R Marthan; J M Tunon-de-Lara
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

Review 4.  Molecular regulation of mast cell development and maturation.

Authors:  Chenxiong Liu; Zhigang Liu; Zhilong Li; Yaojiong Wu
Journal:  Mol Biol Rep       Date:  2009-07-31       Impact factor: 2.316

5.  IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.

Authors:  Matthew R Silver; Alexander Margulis; Nancy Wood; Samuel J Goldman; Marion Kasaian; Divya Chaudhary
Journal:  Inflamm Res       Date:  2009-09-18       Impact factor: 4.575

6.  The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response.

Authors:  Paul T Thevenot; Ashwin M Nair; Jinhui Shen; Parisa Lotfi; Cheng-Yu Ko; Liping Tang
Journal:  Biomaterials       Date:  2010-02-24       Impact factor: 12.479

Review 7.  The cytokine network in asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

8.  Actin reorganization is involved in vasoactive intestinal peptide induced human mast cells priming to fraktalkine-induced chemotaxis.

Authors:  Amr E El-Shazly
Journal:  Int J Gen Med       Date:  2008-11-30

9.  Asthma: eosinophil disease, mast cell disease, or both?

Authors:  Peter Bradding
Journal:  Allergy Asthma Clin Immunol       Date:  2008-06-15       Impact factor: 3.406

10.  Airway smooth muscle proliferation and survival is not modulated by mast cells.

Authors:  D Kaur; F Hollins; R Saunders; L Woodman; A Sutcliffe; G Cruse; P Bradding; C Brightling
Journal:  Clin Exp Allergy       Date:  2009-12-16       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.